Exploring Brazilin as a Potential Breast Cancer Therapy via Molecular Dynamics Simulation Targeting ERα, 17β-HSD1, and NUDT5 Receptors
DOI:
https://doi.org/10.15408/jkv.v11i2.46465Keywords:
Brazilin, breast cancer, ERα, molecular dynamics simulation, NUDT5, 17-β-HSD-1Abstract
Breast cancer remains one of the leading causes of cancer-related mortality worldwide, suggesting the need for novel therapeutic agents with greater efficacy and fewer side effects. Brazilin, a natural flavonoid compound isolated from Caesalpinia sappan L., has shown promising anticancer activity, particularly against breast cancer cells. This study explores the therapeutic potential of brazilin by evaluating its interactions with three key molecular targets: estrogen receptor alpha (ERα), 17β-hydroxysteroid dehydrogenase 1 (17β-HSD1), and Nudix hydrolase 5 (NUDT5). Using molecular dynamics (MD) simulations, the study assesses the stability and binding interactions of complex systems. The results indicate that brazilin forms a stable complex with ERα, demonstrated by a low RMSD (2.6 Å) and strong hydrogen bonding with Glu353, occupancies of 97.8%, and minimal flexibility at the binding site (average RMSF < 2.5 Å). The binding free energy (ΔG Total) for the ERα–brazilin complex was -54.28 kcal/mol, indicating a stronger affinity than the reference ligand 4-hydroxytamoxifen. Brazilin also showed favorable binding with 17β-HSD1 and NUDT5, with binding energies of -39.71 kcal/mol and -23.23 kcal/mol, respectively. These findings suggest that brazilin may modulate critical targets involved in breast cancer progression, particularly in hormone receptor-positive subtypes. Further experimental validation is necessary to confirm its efficacy and optimize its therapeutic potential.
Downloads
References
1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778-789. doi:10.1002/ijc.33588
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
3. Mutha RE, Tatiya AU, Surana SJ. Flavonoids as natural phenolic compounds and their role in therapeutics: an overview. Futur J Pharm Sci. 2021;7(1):25. doi:10.1186/s43094-020-00161-8
4. Syamsunarno MRA, Safitri R, Kamisah Y. Protective Effects of Caesalpinia sappan Linn. and Its Bioactive Compounds on Cardiovascular Organs. Front Pharmacol. 2021;12. doi:10.3389/fphar.2021.725745
5. Zanin JLB, De Carvalho BA, Salles Martineli P, et al. The Genus Caesalpinia L. (Caesalpiniaceae): Phytochemical and Pharmacological Characteristics. Molecules. 2012;17(7):7887-7902. doi:10.3390/molecules17077887
6. Vij T, Anil PP, Shams R, Dash KK, Kalsi R, Pandey VK, Harsanyi E, Kovacs B, Shaikh AM. A Comprehensive Review on Bioactive Compounds Found in Caesalpinia sappan. Molecules. 2023;28(17):6247. doi:10.3390/molecules28176247
7. Raptania CN, Zakia S, Fahira AI, Amalia R. Article review: Brazilin as potential anticancer agent. Front Pharmacol. 2024;15. doi:10.3389/fphar.2024.1355533
8. Yang X, Liang Y, Zhao L, Chen L, Yang Y, Wang J, Yan L, Zhang S, Liu X, Zhang H. Brazilin Inhibits the Invasion and Metastasis of Breast Cancer. Biol Pharm Bull. 2023;46(6):b22-00637. doi:10.1248/bpb.b22-00637
9. He D, Tan X ning, Li L pei, Gao W hui, Tian X fei, Zeng P hua. Brazilin Actuates Ferroptosis in Breast Cancer Cells via p53/SLC7A11/GPX4 Signaling Pathway. Chin J Integr Med. 2024;30(11):1001-1006. doi:10.1007/s11655-024-4104-y
10. Handayani S, Susidarti RA, Udin Z, Meiyanto E, Jenie RI. Brazilein in Combination with Cisplatin Inhibit Proliferation and Migration on Highly Metastatic Cancer Cells, 4T1. Indones J Biotechnol. 2017;21(1):38. doi:10.22146/ijbiotech.26106
11. Hernández-Moreno A, Nava-Tapia DA, Zuñiga-Eulogio MD, et al. Anti-Migratory Activity of Brazilin Chemodiversification on Breast Cancer Cells. Sci Pharm. 2025;93(1):4. doi:10.3390/scipharm93010004
12. Septian AD, Wardani GA, Mardianingrum R, Ruswanto R. The Virtual Screening of Flavonoid Derivatives on Progesterone, Estrogen, and HER-2 Receptor for Breast Cancer Treatment Candidate. Jurnal Kimia Valensi. 2023;9(1):163-182. doi:10.15408/jkv.v9i1.31482
13. Read A, Natrajan R. Splicing dysregulation as a driver of breast cancer. Endocr Relat Cancer. 2018;25(9):R467-R478. doi:10.1530/ERC-18-0068
14. Giacinti L, Claudio PP, Lopez M, Giordano A. Epigenetic Information and Estrogen Receptor Alpha Expression in Breast Cancer. Oncologist. 2006;11(1):1-8. doi:10.1634/theoncologist.11-1-1
15. Aka JA, Zerradi M, Houle F, Huot J, Lin SX. 17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration. Breast Cancer Research. 2012;14(3):R92. doi:10.1186/bcr3207
16. Qian J, Ma Y, Tahaney WM, et al. The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth. Breast Cancer Research. 2024;26(1):23. doi:10.1186/s13058-024-01778-w
17. Hollingsworth SA, Dror RO. Molecular Dynamics Simulation for All. Neuron. 2018;99(6):1129-1143. doi:10.1016/j.neuron.2018.08.011
18. Nurlelasari N, Firdaus ARR, Harneti D, Indrayati N, Baroroh U, Yusuf M. Computational study of the potential molecular target for antibreast cancer activity of limonoid derivatives from chisocheton sp. J Appl Pharm Sci. 2020;10(2):7-12. doi:10.7324/JAPS.2020.102002
19. Astriany D, Baroroh U, Umam K. Molecular Docking of Brazilin from Secang Wood Plant (Caesalpinia sappan L.) as an Anti-Breast Cancer. al Kimiya. 2024;11(1):68-76. doi:10.15575/ak.v11i1.35590
20. Baroroh U, Setiani NA, Mardiah I, Astriany D, Yusuf M. Computational Design of Nanobody Binding to Cortisol to Improve Their Binding Affinity Using Molecular Docking and Molecular Dynamics Simulations. Indonesian Journal of Chemistry. 2022;22(1):515. doi:10.22146/ijc.71480
21. Mahmud S, Uddin MAR, Zaman M, et al. Molecular docking and dynamics study of natural compound for potential inhibition of main protease of SARS-CoV-2. J Biomol Struct Dyn. 2021;39(16):6281-6289. doi:10.1080/07391102.2020.1796808
22. Wang E, Sun H, Wang J, et al. End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. Chem Rev. 2019;119(16):9478-9508. doi:10.1021/acs.chemrev.9b00055
23. Shaw DE, Maragakis P, Lindorff-Larsen K, et al. Atomic-Level Characterization of the Structural Dynamics of Proteins. Science (1979). 2010;330(6002):341-346. doi:10.1126/science.1187409
24. Guterres H, Im W. Improving Protein-Ligand Docking Results with High-Throughput Molecular Dynamics Simulations. J Chem Inf Model. 2020;60(4):2189-2198. doi:10.1021/acs.jcim.0c00057
25. Hollingsworth SA, Dror RO. Molecular Dynamics Simulation for All. Neuron. 2018;99(6):1129-1143. doi:10.1016/j.neuron.2018.08.011
26. J. R. Yunta M. It Is Important to Compute Intramolecular Hydrogen Bonding in Drug Design? American Journal of Modeling and Optimization. 2017;5(1):24-57. doi:10.12691/ajmo-5-1-3
27. Nettles KW, Greene GL. Ligand Control of Coregulator Recruitment to Nuclear Receptors. Annu Rev Physiol. 2005;67(1):309-333. doi:10.1146/annurev.physiol.66.032802.154710
28. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen. Cell. 1998;95(7):927-937. doi:10.1016/S0092-8674(00)81717-1
29. Marchais-Oberwinkler S, Henn C, Möller G, Klein T, Negri M, Oster A, Spadaro A, Werth R, Wetzel M, Xu K, Frotscher M, Hartmann RW, Adamski J. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development. J Steroid Biochem Mol Biol. 2011;125(1-2):66-82. doi:10.1016/j.jsbmb.2010.12.013
30. Patel P, Prasad A, Srivastava K, Singh SS, Chakrabarty D, Misra P. Updates on steroidal alkaloids and glycoalkaloids in Solanum spp.: Biosynthesis, in vitro production and pharmacological values. In: 2021:99-127. doi:10.1016/B978-0-12-819487-4.00012-4
31. Tian JL, Zhao M, Xu JY, Lv TM, Liu XC, Sun S, Guan Q, Zhou ZC, Wu J, Zhao MY, Li Y, Liu HX, Niu SL, Hu P. Inhibitory Mechanism of Prenylated Flavonoids Isolated from Mulberry Leaves on α-Glucosidase by Multi-Spectroscopy and Molecular Dynamics Simulation. J Agric Food Chem. 2023;71(23):9135-9147. doi:10.1021/acs.jafc.3c00776
32. Gupta M, Ahmad J, Ahamad J, Kundu S, Goel A, Mishra A. Flavonoids as promising anticancer therapeutics: Contemporary research, nanoantioxidant potential, and future scope. Phytotherapy Research. 2023;37(11):5159-5192. doi:10.1002/ptr.7975
33. Hou T, Wang J, Li Y, Wang W. Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations. J Chem Inf Model. 2011;51(1):69-82. doi:10.1021/ci100275a
34. Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015;10(5):449-461. doi:10.1517/17460441.2015.1032936
35. McLennan AG. The Nudix hydrolase superfamily. Cell Mol Life Sci. 2006;63(2):123-143. doi:10.1007/s00018-005-5386-7
36. Wu Y, Hsieh T chen, Wu JM, Wang X, Christopher JS, Pham AH, Swaby JDL, Lou L, Xie ZR. Elucidating the Inhibitory Effect of Resveratrol and Its Structural Analogs on Selected Nucleotide-Related Enzymes. Biomolecules. 2020;10(9):1223. doi:10.3390/biom10091223
37. Carreras-Puigvert J, Zitnik M, Jemth AS, Carter M, Unterlass JE, Hallstrom B, Loseva O, Karem Z, Calderon-Montano JM, Lindskog C, Edqvist PH, Matuszewski DM, Blal HA, Berntsson RPA, Haggblad M, Martens U, Studham M, Lundgren B, Wahlby C, Sonnhammer ELL, Lundberg E, Stenmark P, Zupan B, Helleday T. A comprehensive structural, biochemical and biological profiling of the human NUDIX hydrolase family. Nat Commun. 2017;8(1):1541. doi:10.1038/s41467-017-01642-w
38. Garro HA, Pungitore CR. DNA Related Enzymes as Molecular Targets for Antiviral and Antitumoral Chemotherapy. A Natural Overview of the Current Perspectives. Curr Drug Targets. 2018;20(1):70-80. doi:10.2174/1389450119666180426103558
39. Sinuhaji TRF, Ramadhani S, Setiawan VK, Baroroh U. Targeting diabetes with flavonoids from Indonesian medicinal plants: a review on mechanisms and drug discovery. Naunyn Schmiedebergs Arch Pharmacol. Published online April 9, 2025. doi:10.1007/s00210-025-04139-2
40. Page BDG, Valerie NCK, Wright RHG, Wallner O, Isaksson R, Carter M, Rudd SG, Loseva O, Jemth AS, Almlof I, Font-Mateu J, Llona-Minguez S, Baranczewski P, Jeppsson F, Homan E, Almqvist H, Axelsson H, Regmi S, Lena-Gustavsson AL, Lundback T, Scobie M, Stromberg K, Stenmark P, Beato M, Helleday T. Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells. Nat Commun. 2018;9(1):250. doi:10.1038/s41467-017-02293-7
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Umi Baroroh; Jasmine Aulia Dasilva; Melvia Sundalian, Dewi Astriany, Arif Nur Muhammad Ansori, Jonie C. Yee
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
